Dr. Robert on Next Steps Following the Phase III COMBI-v Study in Melanoma

Caroline Robert, MD, PhD
Published: Thursday, Oct 13, 2016



Caroline Robert, MD, PhD, Head of Dermatology, Institute Gustave-Roussy, discusses the next steps following the results of the phase III COMBI-v study in BRAF-mutant melanoma.

The study evaluated the efficacy of the combination of dabrafenib (Tafinlar) plus trametinib (Mekinist) compared with vemurafenib (Zelboraf) monotherapy in patients with BRAF V600 mutation-positive advanced melanoma.

Next steps should focus on developing a better understanding of which subgroups of patients are responding best, and for the longest durations, says Robert. She also recommends a focus on more biomarker research, as well as an examination of potential combinations with immunotherapy that do not add too much toxicity.


Caroline Robert, MD, PhD, Head of Dermatology, Institute Gustave-Roussy, discusses the next steps following the results of the phase III COMBI-v study in BRAF-mutant melanoma.

The study evaluated the efficacy of the combination of dabrafenib (Tafinlar) plus trametinib (Mekinist) compared with vemurafenib (Zelboraf) monotherapy in patients with BRAF V600 mutation-positive advanced melanoma.

Next steps should focus on developing a better understanding of which subgroups of patients are responding best, and for the longest durations, says Robert. She also recommends a focus on more biomarker research, as well as an examination of potential combinations with immunotherapy that do not add too much toxicity.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Evolving Roles for Targeted Melanoma Therapies: Assessing Rapid Progress in the Field and Looking Toward Future CombinationsFeb 28, 20191.5
Publication Bottom Border
Border Publication
x